Jan 7, 2026 08:17AM
Jan 7, 2026 08:15AM
Jan 7, 2026 08:15AM
Dec 30, 2025 08:35AM
Dec 30, 2025 08:35AM
Oct 28, 2025 08:45AM
Oct 28, 2025 08:45AM Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Oct 20, 2025 08:45AM
Oct 20, 2025 08:45AM
Oct 13, 2025 08:46AM
Oct 13, 2025 08:45AM
Sep 17, 2025 09:00AM
Sep 17, 2025 09:00AM
Sep 5, 2025 08:45AM Palisade Bio receives Health Canada clearance for phase 1b trial
Sep 5, 2025 08:45AM
Aug 7, 2025 09:15AM
Aug 7, 2025 09:15AM
Sep 25, 2024 08:01AM
Sep 25, 2024 08:00AM
Aug 13, 2024 08:05AM
May 29, 2024 06:47AM Ladenburg Thalmann Reiterates Buy Rating on Palisade Bio Inc. (PALI)
May 14, 2024 08:05AM
Mar 27, 2024 08:00AM
Feb 8, 2024 08:05AM
Nov 22, 2022 08:57AM
Nov 22, 2022 08:36AM
Nov 22, 2022 08:35AM
Nov 22, 2022 08:35AM Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
Nov 18, 2022 08:05AM
Nov 18, 2022 08:05AM
Nov 18, 2022 08:05AM
May 13, 2022 09:00AM
May 5, 2022 08:31AM
May 5, 2022 08:30AM
May 2, 2022 08:35AM Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements
Apr 29, 2022 08:05AM
Mar 22, 2022 08:31AM
Mar 22, 2022 08:30AM
Mar 18, 2022 08:30AM
Mar 16, 2022 08:04AM
Mar 16, 2022 08:00AM
Dec 8, 2021 08:01AM Palisade Bio Inc. (PALI) Granted US Patent for Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus
Dec 8, 2021 08:00AM
Aug 24, 2021 08:15AM
Aug 20, 2021 09:28AM
Aug 20, 2021 09:25AM
Jul 29, 2021 08:16AM
Jul 29, 2021 08:15AM
Jun 15, 2021 08:15AM Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function an
May 13, 2021 07:04AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All